Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05138718 · ClinicalTrials.gov registry record
FDG an Myocardial Infarction: The PIAF Trial
A clinical trial of History of Myocardial Infarction, sponsored by International Atomic Energy Agency.
- Recruiting
- Registry status
- 2,041
- Enrollment target
- 1
- Study location
NCT05138718: Recruiting study of History of Myocardial Infarction, sponsored by International Atomic Energy Agency.
NCT05138718 is a study of History of Myocardial Infarction that is actively recruiting participants, run by International Atomic Energy Agency. The registered enrollment target is 2,041 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05138718, a study of History of Myocardial Infarction, is actively recruiting participants, sponsored by International Atomic Energy Agency.
- RECRUITING
- Registry status
- 2,041 participants
- Enrollment target
- 1
- Study location
Study Summary
In order to define distinct and reliable arterial 18Fluorodeoxyglucose (FDG) thresholds identifying patients at risk for cardiovascular events, patients with a history of myocardial infarction will be included in this international multicenter trial. Non-enhanced whole-body FDG PET/CT will be performed in all patients and the arterial FDG uptake in the carotid arteries as well as the aorta will be quantified by calculating different uptake parameters. In addition, FDG uptake in hematopoietic tissues (spleen, bone marrow), visceral adipose tissue (VAT) and different brain regions (e. g. amygdala) will be measured. Furthermore, specific blood biomarkers including genetic biomarkers, which are linked to atherosclerotic disease with predictive power for future cardiovascular events, will be analyzed in a subgroup of patients. In part 2 of the trial, a 4-year follow-up period will be analyzed with a focus on the prediction of cardiovascular events (acute coronary syndrome, non-fatal ischemic stroke, ischemic cardiac death, other causes of death, coronary/vascular revascularization, new-onset of angina, symptomatic peripheral arterial disease and heart failure). The predictive value of the arterial, hematopoietic and cerebral FDG uptake parameters as well as of the specific blood and genetic biomarkers will be determined.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 18F-FDG PET/CT
Study Locations (1)
Massachusetts
- Massachusetts General Hospital, Havard Medical School - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,041 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2026-07-01 |
What NCT05138718 shows while recruiting
NCT05138718 is an observational study that tracks outcomes without assigning an intervention. Its 2,041 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with History of Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which 18F-FDG PET/CT is the first listed.
NCT05138718 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05138718 about?
NCT05138718 is a clinical study titled "FDG an Myocardial Infarction: The PIAF Trial". In order to define distinct and reliable arterial 18Fluorodeoxyglucose (FDG) thresholds identifying patients at risk for cardiovascular events, patients with a history of myocardial infarction will be included in this international multicenter trial. Non-enhanced whole-body FDG PET/CT will be perfor...
What is the current status of trial NCT05138718?
This trial is currently recruiting. The enrollment target is 2,041 participants. The study started on 2021-12-01. Estimated completion is 2026-07-01.
What conditions does trial NCT05138718 study?
This clinical trial studies the following conditions: History of Myocardial Infarction.
What interventions are being tested in trial NCT05138718?
The interventions under investigation include: 18F-FDG PET/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05138718?
This trial is sponsored by International Atomic Energy Agency, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05138718 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06825897 · 2,039 participants · NA
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
- NCT06833476 · 2,044 participants
TTVR STRONG Under Coverage With Evidence Development (CED) Study
- NCT05688982 · 2,049 participants · NA
MOLAR: Mapping Oral Health and Local Area Resources
- NCT05050084 · 2,050 participants · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI